Expertise

Faruk Abdullah

Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING

Expertise:

Consulting (Strategy Management & Regulatory)

Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence. Prior to joining EVERSANA MANAGEMENT CONSULTING he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data and focused on shaping and executing strategic initiatives for large- and mid-cap life sciences companies.

In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts, developing products in both the therapeutic and medical device spaces. He has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem and offered insights on how organizations can rethink the development and integration of analytic capabilities to inform strategic decisions.

Faruk holds an MBA from Harvard Business School and a BS in electrical engineering from Northwestern University.

Articles by Faruk Abdullah

Learning How to Play Dilution Dodgeball

The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market.  Developing and successfully commercializing a biopharma product is no small undertaking. The multi-year journey is fraught with clinical, financial and operational uncertainties that many companies fail […]

Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth

As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market […]

The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value

The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their clinical outcomes. The clinical consequences of this will lead to compromised patient outcomes and further healthcare cost increases. This […]

Moving Forward in Pharma: Reigniting Revenue for Mature Brands

The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in […]

Three Keys To Value For Unlocking The Promise Of Cell Therapies

For several years cell therapies have been commanding the headlines with their novel scientific approach and remarkable results in improving patient outcomes. The allure of cell therapy has raised expectations not only for what it could do from a patient standpoint but also how it could potentially transform the way we think about treating and […]

The Chronic Microcap Trap: How Launch Is The Escape for True Growth

Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation. […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.